1. Home
  2. TOVX vs BFRI Comparison

TOVX vs BFRI Comparison

Compare TOVX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.23

Market Cap

14.7M

Sector

Health Care

ML Signal

HOLD

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$1.13

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOVX
BFRI
Founded
2001
1997
Country
United States
United States
Employees
N/A
94
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7M
13.2M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
TOVX
BFRI
Price
$0.23
$1.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$1.00
$2.75
AVG Volume (30 Days)
1.6M
399.4K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
89.07
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$14.36
Revenue Next Year
N/A
$16.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.57
52 Week High
$0.86
$1.21

Technical Indicators

Market Signals
Indicator
TOVX
BFRI
Relative Strength Index (RSI) 39.75 57.69
Support Level $0.23 $0.77
Resistance Level $0.27 $1.13
Average True Range (ATR) 0.02 0.09
MACD -0.00 0.01
Stochastic Oscillator 15.32 62.87

Price Performance

Historical Comparison
TOVX
BFRI

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Share on Social Networks: